Live feed14:03:00·1408dPRReleasevia Quantisnowbluebird bio Announces FDA Approval of ZYNTEGLO®, the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell TransfusionsByQuantisnow·Wall Street's wire, on your screen.BLUE· bluebird bio Inc.Health Care
